newsfilter
← Latest News
GlobeNewswire·

Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer

  • Nurix Therapeutics, Inc. appointed Arati V. Rao, M.D., as chief medical officer on November 11, 2026.
  • Dr. Rao brings over 20 years of experience in academic hematology, oncology, clinical development, & global regulatory submissions.
  • She will lead Nurix's clinical development organization while advancing the registrational program for bexobrutideg & its broader pipeline.
  • Dr. Rao joins from Pfizer, where she served as vice president of late-stage clinical development & global franchise head for PF-08634404.
  • Previously at Seagen, she led early-stage clinical development for antibody-drug conjugates & immunotherapy programs.
  • She previously served as clinical development lead for Tecartus at Kite-Gilead, supporting its 2020 FDA approval for mantle cell lymphoma.
  • Before industry roles, Dr. Rao was an associate professor of medicine at Duke University focusing on hematologic malignancies.
  • Nurix's clinical oncology pipeline includes bexobrutideg (a BTK degrader co-developed with Roche) & NX-1607 (a CBL-B inhibitor).
  • The company's autoimmune disease pipeline features bexobrutideg with Roche & an IRAK4 degrader with Gilead.
  • Nurix maintains collaboration agreements with Gilead Sciences, Sanofi, & Pfizer for multiple drug candidates with co-development options.
Company
Nurix Therapeutics, Inc.
Keywords
Nasdaq:NRIX, Nurix Therapeutics, Inc.